Related Experiment Video
Updated: Mar 13, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
13.4K
Anticancer effect of thalidomide in vitro on human osteosarcoma cells
Jianwei Zhu1, Ya Yang2, Sihong Liu1
1Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China.
Oncology Reports
|October 18, 2016
Summary
Thalidomide effectively inhibits osteosarcoma cell growth and induces apoptosis. This study suggests thalidomide
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a prevalent high-grade malignant bone tumor in children and adolescents.
- Thalidomide has demonstrated efficacy in treating various malignancies.
Purpose of the Study:
- To investigate the effects of thalidomide on osteosarcoma cells.
- To evaluate thalidomide's potential as an antitumor drug for osteosarcoma therapy.
Main Methods:
- Cytotoxicity assays were performed on MG-63 and U2OS osteosarcoma cell lines.
- Apoptosis, cell cycle, mitochondrial membrane potential (ΔΨm), and reactive oxygen species (ROS) levels were assessed.
- Western blot analysis was used to examine the expression of key proteins (Bcl-2, Bax, caspase-3, NF-κB).
Main Results:
- Thalidomide inhibited osteosarcoma cell proliferation in a dose- and time-dependent manner.
- Apoptosis was induced, evidenced by morphological changes and increased apoptosis rates.
- Cell cycle arrest at the G0/G1 phase and increased ROS levels were observed.
- Thalidomide altered the expression of apoptosis-related proteins, including decreased Bcl-2 and NF-κB, and increased Bax and caspase-3.
Conclusions:
- Thalidomide induces apoptosis and cell cycle arrest in osteosarcoma cells.
- The drug disrupts mitochondrial membrane potential and upregulates ROS.
- These findings support thalidomide's potential as an effective therapeutic agent for osteosarcoma.
